Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024

BUENOS AIRES, Argentina, April 15, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare dise...

2024-04-16 02:00 730

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90% SYDNE...

2024-04-15 20:30 833

Wound Care Plus, LLC Revolutionizes Wound Management with ARANZ Medical's Silhouette Solution

CHRISTCHURCH, New Zealand, April 15, 2024 /PRNewswire/ -- Wound Care Plus, LLC, a leading provider of mobile wound care services in the US, has announced a groundbreaking partnership with ARANZ Medical to integrate ARANZ Medical's innovative Silhouette wound assessment solution into their wound c...

2024-04-15 20:00 621

GenScript Biotech officially joins SBTi to fulfill its sustainability commitment

PISCATAWAY, N.J., April 15, 2024 /PRNewswire/ -- On April 15, GenScript Biotech Corporation ("GenScript"), a world's leading technology and service provider of life science R&D and manufacture, announced that it has joined The Science Based Targets initiative (SBTi) and submitted the Science Base...

2024-04-15 15:04 681

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO

SINGAPORE, April 15, 2024 /PRNewswire/ -- Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @South San Francisco[1] from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships ...

2024-04-15 14:15 764

【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations

NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to disc...

2024-04-12 21:00 1580

Empowering Lives with COOLiFY: TORRAS Joins Forces with Autistic Families to Advance Technological Excellence and Foster a Deep Sense of Love and Care

NEW YORK, April 11, 2024 Capitalizing on the global significance of World Autism Awareness Day onApril 2nd, TORRAS, in tandem with the promotion of COOLiFY Cyber's latest offerings, has crafted an innovative campaign that seamlessly integrates brand mission with social responsibility: "Stay Cool ...

2024-04-11 22:00 1108

Empowering Lives with COOLiFY: TORRAS Joins Forces with Autistic Families to Advance Technological Excellence and Foster a Deep Sense of Love and Care

Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer

SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. John Lee, MD, PhD, as its Chief Medical Office...

2024-04-11 14:59 1310

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th April poster session of the 2024 American Cancer Research Society (AACR) Annual Meeting held inSan Diego,...

2024-04-11 14:56 999

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

NEWARK, Del., April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conferenc...

2024-04-10 21:00 1165

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

BEIJING and PARIS, April 10, 2024 /PRNewswire/ -- On March 15th, Biologics 2024 successfully concluded inLondon, with 650 pharmaceutical, biotechnology, and academic representatives and over 50 exhibitors engaging in high-level discussions on the latest innovations in biologics discovery and deve...

2024-04-10 14:19 859

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...

2024-04-09 23:14 1384

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...

2024-04-09 22:10 1080

Meeting the Future | TIANMA Makes a Strong Appearance at 2024 Embedded World

NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- The world's largest embedded exhibition—— Embedded World 2024, is being held grandly at the Exhibition Centre Nuremberg from 9th to 11th April. Numerous leading companies around the world have brought exciting technologies and innovative services....

2024-04-09 22:00 1080

Meeting the Future | TIANMA Makes a Strong Appearance at 2024 Embedded World

Datasea Announces Intent of its CEO to Purchase Up $3,000,000 of its Common Stock in Open Market Purchases

BEIJING, April 9, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and Ch...

2024-04-09 22:00 2887

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...

2024-04-09 19:59 841

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...

2024-04-09 19:00 1315

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...

2024-04-09 19:00 990

China's Yunhong Group inks cooperation to support overseas expansion

BEIJING, April 9, 2024 /PRNewswire/ -- On April 3, the signing ceremony between Global Digital Trade Port (Hainan) Enterprise Management Co., Ltd. and Yunhong Group was held inBeijing, and the two sides will carry out in-depth cooperation in the field of health food.

2024-04-09 15:50 1093

China's Yunhong Group inks cooperation to support overseas expansion

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...

2024-04-09 08:30 1081

12 3 4 5 ... 253